SSgA Funds Management, Inc. recently announced the acquisition of new stake in BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX). The institutional investor has increased its shareholding in the Healthcare company by 171.11% to 15.58 million shares with purchase of 9.83 million shares. This fresh investment now brings its stake to 8.83% valued currently at $63.4 million. In addition, Baker Bros. Advisors LP raised its holdings by 2.82 million to 13.77 million shares. And BlackRock Fund Advisors has lifted its position by 5.60% or 0.65 million shares – to 12.3 million shares.

With over 15.24 million BioCryst Pharmaceuticals Inc. (BCRX) shares trading Monday and a closing price of $4.15 on the day, the dollar volume was approximately $63.26 million. The shares have shown a positive weekly performance of 4.67% and its price on 08/31/20 gained nearly 4.53%. Currently, there are 161.57M common shares owned by the public and among those 161.09M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 9 analysts who have offered their price forecasts for BCRX have a consensus price objective of $8.50. The analysts have set the share’s price value over the next 12 months at a high of $13.00 and a low of $4.50 should the stock experience a downside. Incidentally, analysts’ outlook for the BioCryst Pharmaceuticals Inc. stock is 2.10 for the next 12 months. But an upside of 68.08% will see the stock hit the forecast high price target while mean target price for the stock is $8.00.

Insiders at the company have transacted a total of 22 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 22 of these insider trades were purchases, accounting for 284,128 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.

The top 3 mutual fund holders in BioCryst Pharmaceuticals Inc. are SPDR S&P Biotech ETF, Vanguard Total Stock Market Index, and iShares Russell 2000 ETF. SPDR S&P Biotech ETF owns 13.54 million shares of the company’s stock, all valued at over $55.1 million. The company sold -0.14 million shares recently to bring their total holdings to about 7.68% of the shares outstanding. Vanguard Total Stock Market Index bought 1576.0 shares to see its total holdings expand to 5.0 million shares valued at over $20.34 million and representing 2.83% of the shares outstanding. iShares Russell 2000 ETF sold -0.15 million shares to bring its total holdings to over 3.21 million shares at a value of $13.05 million. iShares Russell 2000 ETF now owns shares totaling to 1.82% of the shares outstanding.

Shares of BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) opened at $4.20, up $0.23 from a prior closing price of $3.97. However, the script later closed the day at $4.15, up 4.53%. The company’s stock has a 5-day price change of 4.67% and -12.26% over the past three months. BCRX shares are trading 20.29% year to date (YTD), with the 12-month market performance up to 38.80% higher. It has a 12-month low price of $1.38 and touched a high of $6.29 over the same period. Currently, 15.24 million shares have been traded, compared to an average intraday trading volume of 6.90 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.83%, -8.38%, and 18.21% respectively.

Institutional ownership of BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares accounts for 77.00% of the company’s 161.57M shares outstanding. Mutual fund holders own 26.72%, while other institutional holders and individual stakeholders account for 47.84% and 12.67% respectively.

It has a market capitalization of $723.47M and a beta (3y monthly) value of 2.60. The earnings-per-share (ttm) stands at -$0.84. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.25% over the week and 6.47% over the month.

Analysts forecast that BioCryst Pharmaceuticals Inc. (BCRX) will achieve an EPS of -$0.25 for the current quarter, -$0.2 for the next quarter and -$0.83 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.28 while analysts give the company a high EPS estimate of -$0.17. Comparatively, EPS for the current quarter was -$0.34 a year ago. Earnings per share for the fiscal year are expected to increase by 4.00%, and 10.80% over the next financial year. EPS should grow at an annualized rate of 19.90% over the next five years, compared to -6.80% over the past 5-year period.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate BioCryst Pharmaceuticals Inc. (BCRX) as a “Moderate Buy” at a consensus score of 2.10. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 3 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the BCRX, a number of firms have released research notes about the stock. BTIG Research stated their Neutral rating for the stock in a research note on June 17, 2020, with the firm’s price target at. Barclays coverage for the BioCryst Pharmaceuticals Inc. (BCRX) stock in a research note released on May 05, 2020 offered a Overweight rating with a price target of $7. BofA/Merrill was of a view on November 15, 2019 that the stock is Buy, while RBC Capital Mkts gave the stock Sector Perform rating on May 24, 2019, issuing a price target of $16- $4.50. Piper Jaffray on their part issued Overweight rating on November 16, 2018.